Financial reports
20-F/A
2023 FY
Annual report (foreign) (amended)
26 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
20-F
2022 FY
Annual report (foreign)
22 Mar 23
20-F/A
2021 FY
Annual report (foreign) (amended)
9 Sep 22
20-F
2021 FY
Annual report (foreign)
16 Mar 22
20-F
2020 FY
Annual report (foreign)
23 Feb 21
20-F
2019 FY
Annual report (foreign)
12 Mar 20
20-F/A
2018 FY
Annual report (foreign) (amended)
30 Jul 19
20-F/A
2018 FY
Annual report (foreign) (amended)
5 Jun 19
20-F
2018 FY
Annual report (foreign)
28 Mar 19
Current reports
6-K
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
17 Apr 24
6-K
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
10 Apr 24
6-K
BioLineRx Announces $6 Million Registered Direct Offering
1 Apr 24
6-K
BioLineRx Reports 2023 Financial Results and Recent Corporate
26 Mar 24
6-K
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
4 Mar 24
6-K
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
28 Feb 24
6-K
Current report (foreign)
16 Feb 24
6-K
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
21 Dec 23
6-K
Current report (foreign)
12 Dec 23
6-K
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
20 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Apr 24
S-8
Registration of securities for employees
29 Dec 23
F-3
Shelf registration (foreign)
29 Dec 23
S-8
Registration of securities for employees
20 Jan 23
424B5
Prospectus supplement for primary offering
20 Sep 22
424B5
Prospectus supplement for primary offering
3 Sep 21
POS AM
Prospectus update (post-effective amendment)
23 Feb 21
424B5
Prospectus supplement for primary offering
21 Jan 21
FWP
Free writing prospectus
19 Jan 21
FWP
Free writing prospectus
19 Jan 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
8 Jan 24
CT ORDER
Confidential treatment order
21 Sep 21
EFFECT
Notice of effectiveness
25 Feb 21
EFFECT
Notice of effectiveness
12 Jan 21
CORRESP
Correspondence with SEC
11 Jan 21
UPLOAD
Letter from SEC
6 Jan 21
EFFECT
Notice of effectiveness
13 Aug 20
EFFECT
Notice of effectiveness
6 Jul 20
CORRESP
Correspondence with SEC
1 Jul 20
UPLOAD
Letter from SEC
1 Jul 20
Ownership
SC 13D
Hong Seng Technology Ltd
26 Oct 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
NOVARTIS PHARMA AG
16 Feb 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13G/A
Senvest Management, LLC
12 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
6 Jan 21
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
3 Nov 20
SC 13G
ARMISTICE CAPITAL, LLC
5 Jun 20
SC 13G
Altium Capital Management LP
5 Jun 20